Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
6 participants
INTERVENTIONAL
2013-09-30
2015-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73
NCT06995976
Novel Gallium Imaging in Hepatocellular Carcinoma
NCT03116945
68Ga-Pentikra PET/CT Imaging Study in Healthy Subjects
NCT06856109
[68Ga]Ga-PSMA PET/CT in Hepatocellular Carcinoma: Impact of Multiparametric Dynamic Whole-body Imaging and Kinetic Modeling.
NCT06999837
68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study
NCT06688188
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Gallium-68 citrate
Intravenous bolus injection of 200 MBq of Gallium-68 citrate
Gallium-68 citrate
Single intravenous bolus injection of 200 MBq of Gallium-68 citrate radiopharmaceutical
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gallium-68 citrate
Single intravenous bolus injection of 200 MBq of Gallium-68 citrate radiopharmaceutical
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Turku University Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Anne Roivainen
professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne Roivainen
Role: PRINCIPAL_INVESTIGATOR
Turku University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Turku University Hospital/Turku PET Centre
Turku, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
167/2013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.